Stereotactic radiation vs standard radiation for limited cancer spread
Part of Cancer clinical trials.
This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have a solid tumor cancer that has spread to new spots in up to 5 places (not lymphoma or myeloma)
- You are able to care for yourself (ECOG score 0-2) and expected to live at least 6 months
- You are either currently on cancer treatment that initially worked but now some spots are growing, or you are off treatment and have some growing spots while others are stable
- All growing spots can be safely treated with radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether targeted radiation can control a few growing spots of breast cancer while the rest of the cancer stays stable on your current treatment. It aims to delay the need to switch to a new therapy.
This trial compares two types of highly focused radiation (ablative radiosurgery versus stereotactic radiation in 5 sessions) for people with a small number of metastases in the bone. It aims to find which approach controls these spots with fewer side effects while keeping the treatment “radical,” meaning trying to wipe out the targeted lesions.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
This trial tests whether giving focused, high-dose radiation to spots where the cancer is growing can help control the disease while you stay on your current hormone therapy and/or CDK4/6 inhibitor. It is for people with ER+/HER2- breast cancer that has spread to a few places and is slowly starting to progress.
This trial tests a precise, high-dose radiation treatment (SABR) for people whose cancer has spread to a few spots (up to 5) and is not growing in the brain or been previously treated with radiation in those same spots.
This trial tests whether giving one strong dose of radiation is as good as several smaller doses for people with a small number of cancer spots that have spread. The goal is to find a treatment that is just as effective but more convenient and with fewer side effects.
Hear when a new Oligoprogression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.